Please ensure Javascript is enabled for purposes of website accessibility

Baltimore’s eNeura Inc. concludes Series D financing round

eneuraBaltimore-based eNeura Inc., a privately held medical technology company developing non-invasive, non-drug treatment and prevention of migraine headaches, announced Tuesday it had completed a Series D financing led by investment group Camden Partners Nexus.

Proceeds of the financing round will be used for the commercial expansion of the company’s sTMS mini neuromodulation device for the acute treatment and prevention of migraine.

Following the U.S. Food and Drug Administration clearance of sTMS for acute treatment and prevention of migraine headache in mid 2017, eNeura has launched its newest generation of sTMS (single-pulse Transcranial Magnetic Stimulation) working with headache specialists and neurologists at headache centers across the U.S.


To purchase a reprint of this article, contact reprints@thedailyrecord.com.